Partners and Collaborators

The joint work aims to maximize the potency and efficacy of anti-cancer vaccines and to develop antibodies for the treatment of ovarian cancer and multiple myeloma.
The joint effort has led to the discovery of a new antigen that can be exploited for designing immunotherapeutic regimens against head and neck squamous cell carcinoma (HNSCC).
The joint work aims at the clinical development of Kiromic’s advanced first-in-class micro-particle based oral vaccine, BSK02.
The joint effort is aimed at generating novel immunotherapeutic approaches to cure cancer and state-of-the-art multi-marker serological test to detect cancer at an early stage.
The joint effort is aimed at the development of a Chimeric Antigen Receptor for the treatment of cancer.
The pioneering effort aims to support the growth of the AI-target discovery program at Kiromic.

Advisors

Strategic and Financial Advisor: Provides investment, strategy and financial advisory service
Regulatory Advisor: Full regulatory and accounting services
Legal Services: Provides forecasting, modeling, valuation, market assessment services
Communication Advisor: Provides strategic communication and public affair advisory services
Audit and Tax Services
Copyright © 2018 Kiromic. All rights reserved.